Head-To-Head Analysis: SBC Medical Group (NASDAQ:SBC) versus Q Biomed (OTCMKTS:QBIO)

Q Biomed (OTCMKTS:QBIO) and SBC Medical Group (NASDAQ:SBC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Risk & Volatility

Q Biomed has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, SBC Medical Group has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.

Valuation & Earnings

This table compares Q Biomed and SBC Medical Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q Biomed	N/A	N/A	N/A	$0.05	0.00
SBC Medical Group	$178.46 million	2.16	$46.61 million	$0.41	9.15

SBC Medical Group has higher revenue and earnings than Q Biomed. Q Biomed is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

60.8% of SBC Medical Group shares are owned by institutional investors. 28.2% of Q Biomed shares are owned by insiders. Comparatively, 89.5% of SBC Medical Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Q Biomed and SBC Medical Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q Biomed	0	0	0	0	0.00
SBC Medical Group	1	0	1	0	2.00

SBC Medical Group has a consensus price target of $9.00, indicating a potential upside of 140.00%. Given SBC Medical Group’s stronger consensus rating and higher probable upside, analysts plainly believe SBC Medical Group is more favorable than Q Biomed.

Profitability

This table compares Q Biomed and SBC Medical Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q Biomed	N/A	N/A	N/A
SBC Medical Group	24.28%	24.17%	18.60%

Summary

SBC Medical Group beats Q Biomed on 11 of the 12 factors compared between the two stocks.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

About SBC Medical Group

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.